Smith Research

Scott A. Smith MD PhD

PRIMARY APPOINTMENT:

Associate Professor of Medicine

CONTACT:

UVA Division of Asthma, Allergy, and Clinical Immunology
PO Box 801355
MR-4
Charlottesville, VA

EDUCATION AND TRAINING

Bachelor of Science in Biology, Pre-Medicine
California University of Pennsylvania
California, PA
PhD in Microbiology and Immunology, 2002 “Structure and Function Studies of the Vaccinia Virus Complement Control
Protein.” Mentor Girish J. Kotwal
University of Louisville, School of Medicine, Department of
Microbiology and Immunology
Louisville, KY
Doctor of Medicine
University of Louisville, School of Medicine
Louisville, KY MD

Post Graduate Training

Residency in Internal Medicine
Vanderbilt University Hospital
Nashville, TN Medicine
Fellowship in Infectious Diseases
Division of Infectious Diseases
Vanderbilt University Hospital
Nashville, TN Medicine

RESEARCH SUMMARY

Analogous to work in viral infectious diseases, our work in the field of allergic diseases has several translational goals. The first approach is to directly map the human IgE allergic antibody response, aiming to generate switched variant IgG blocking therapeutics that mitigate anaphylaxis due to accidental exposure. Like identifying neutralizing epitopes, developing blocking therapeutics requires first the mapping of immunodominant pathogenic IgE antibody responses to find those antibodies that would be most effective at functionally blocking anaphylaxis. We have pursued this goal on multiple fronts and have only begun to publish the results, with our peanut IgE work currently in press at the Journal of Allergy and Clinical Immunology. This work is patented, licensed, and currently in therapeutic development.

A second translational goal of our current work is to design hypoallergenic immunotherapeutics. This concept is analogous to using neutralizing human antibodies to create vaccines that elicit immune responses yielding similar antibodies rationally. We use the pathogenic IgE molecule, in collaboration with various structural biology groups, to molecularly define the IgE epitope on key major allergen proteins. These epitopes are then rationally mutated to create hypoallergens (allergen proteins with less IgE binding competence), without alteration of their structure and preserving all other antibody epitopes. These engineered vaccine molecules are highly effective in our murine model at abrogating IgE binding and anaphylaxis induction. We have only begun patenting and publishing this work, with several manuscripts in preparation and one published in PNAS Nexus.

Finally, our third active translational goal is to develop parasite vaccines. Despite it being common knowledge that the IgE antibody response protects us from helminth infections, nothing is known about the antigens or mechanisms of protection. To begin developing novel vaccine strategies to combat helminth infection, we have identified and characterized those immunodominant antigens responsible for profound induction of IgE antibody responses. Patenting is underway, and these initial results are published in the Journal of Allergy and Clinical Immunology. We are actively characterizing these responses in our murine model, using both active and passive protection against infection with the Brugia malayi helminth. Similarly, we have recently begun work with ectoparasites, ticks. It is not widely known that mammals can gain immunity to tick bites, a phenomenon called acquired tick resistance. This immunity is dependent on IgE and basophils. Still, it is otherwise completely unknown. We are expanding a panel of human IgE antibodies from individuals with alpha-gal syndrome, a tick-borne allergic disease, and those who have frequent and recurrent tick bites. Our goal, similar to that with helminths, is to utilize the human IgE antibody response to identify immunodominant antigens and rationally design vaccines that induce active immunity in naive humans.

I plan to continue this translational human B cell research toward the development of antibody therapeutics and the rational design of novel vaccines and immunotherapies. We will develop IgG blocking therapeutics to mitigate against anaphylaxis, use structure-based design to create novel hypoallergenic immunotherapeutics, and continue work on parasite vaccines, developing vaccines based on IgE antibody-antigen discovery.

ONGOING RESEARCH SUPPORT

R01AI182247 (Smith; PI) 3/20/24 – 2/28/29 “Role of IgE in human disease and immunity to ticks” The major goals are to study IgE monoclonal antibodies from human subjects with recurrent tick bites, identify, express, and validate the specific tick proteins targeted, and to characterize the role IgE plays in immunity to tick bites using murine models.

R01AI108884 (Bilgicer/Smith, Co-I) 5/1/20 – 4/30/25 “Designer covalent heterobivalent inhibitors to prevent IgE-dependent allergic reactions” This is an investigator-initiated grant to create inhibitors of human IgE antibodies for therapeutic development.

R01AI146204 (Smith; PI) 9/1/20 – 8/31/25 “Comprehensive antigenic mapping of the human anti-peanut IgE antibody response” This is an investigator-initiated grant to map binding determinants of peanut-specific human IgE mAbs.

R01AI077653 (Pomes/Smith, Co-I) 5/1/20 – 4/30/25 “Antigenic determinants of asthma-associated allergens for design of immunotherapy” This is an investigator-initiated grant to map binding determinants of aeroallergen-specific human IgE mAbs.

75N93024C00070 (Fremont/Smith, Project leader) 9/16/24-9/15/29

“Innovations in Functional B Cell Epitope Discovery” This is an NIH contract awarded to WashU which VUMC has a subaward. Our project is to determine B cell epitopes on tick salivary antigens, both protein and carbohydrate.

R01AI175232 (McGowan/Smith, Co-I) 4/01/23 – 3/31/28 “Defining the Role of Immunoglobulin G4 (IgG4) in Food-Induced Eosinophilic Esophagitis (EoE)” This is a grant to investigate the role that allergen-specific IgG4 antibodies play in EoE disease.

R01DK131070 (Bonami/Smith, Co-I) 12/01/21 – 11/30/26 “The Origins of Human Anti-Insulin B Lymphocytes in Type 1 Diabetes” These studies will enable future investigation of AIBC changes as sensitive biomarkers to predict diabetes onset and identify favorable clinical trial responses.

PENDING RESEARCH SUPPORT COMPLETED RESEARCH SUPPORT

R01AI130459 (Smith; PI) 4/6/17-3/31/24 “Antigenic landscape of the human anti-helminth IgE antibody response” This is an investigator-initiated grant to study the human IgE antibody response to helminth infection.

R21AI154064 (Smith; PI) 7/1/20-6/30/24 “Molecular basis for anaphylaxis due to galactose-alpha-1,3-galactose (alpha-gal)” This is an investigator-initiated development grant to make and characterize alpha-gal specific human IgE mAbs.

Stanley Cohen Innovation Fund (Smith; PI) 7/1/17 – 6/30/19 “Therapeutic repurposing of naturally occurring human peanut-specific IgE monoclonal antibodies” Project description: This is an internal grant to support proof of concept studies testing the therapeutic potential of recombinant human IgG mAbs, derived from pathogenic IgE mAbs.

FARE Clinical Network Award (Smith/Dorris) 1/1/19- 12/31/21 “Vanderbilt University Medical Center Food Allergy Clinical Site” This is an award to support a food allergy clinical network site by partially supporting a research coordinator to recruit and enroll research subjects into clinical trials.

Vanderbilt Discovery Grant (Spiller/Smith; Co-PI) 7/1/16 – 6/30/18 “Identification and Structural Elucidation of Human Allergen Epitopes” Project description: This is an internal grant to support early structural studies of human anti-allergen IgE mAbs.

R21AI123307 (Smith; PI) 12/19/16 – 11/30/18 “Generation and characterization of full-length naturally occurring allergen-specific human IgE mAbs” Project description: This is an investigator-initiated development grant to make food-specific human IgE mAbs from allergic patient’s peripheral blood cells.

K08AI103038 (Smith; PI) 8/13/12 – 7/31/17 “Key determinants of dengue virus neutralization by naturally occurring human mAbs” Project description: This is a mentored career development award to support studies of the human antibody response to natural dengue virus infection.

L30AI090943 (Smith; PI) 7/1/10 – 6/30/16 “Genetic and structural determinants of neutralization by naturally-occurring human monoclonal antibodies to dengue virus” Project description: This is an extramural clinical research loan repayment award to support continued research and career development as a physician scientist.

Pfizer Young Investigator Award (Smith; PI) 7/1/14 – 6/31/16 “Human antibody response to chikungunya virus infection” Project description: This is a young investigator career development award to support studies of the human antibody response to natural chikunguya virus infection.

SE-CD-006 (Smith; Project leader) 3/1/11 – 8/13/12 NIH/NIAID: CDA under U54 AI057157 “Southeast Regional Center of Excellence for Emerging Infections and Biodefense (SERCEB)”; PI of the RCE: Fred Sparling [UNC-CH] “Characterization of rare neutralizing human mAbs to dengue viruses” Project description: This is a career development award to support preliminary studies to characterize rare neutralizing human monoclonal antibodies to dengue viruses.

PUBLICATIONS

Smith S.A.,P. Mullin, J. Parkinson, S.N. Shchelkunov, A.V. Totmenin, V.N. Loparev, R. Srisatjaluk, D.N. Reynolds, K.L. Keeling, D.E. Justus, P.N. Barlow, G.J. Kotwal. Conserved surface-exposed K/R-X-K/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense. J. Virol., Jun. 74(12):5659-66, 2000 [Cover of J. Virol., Oct. 74(20), 2000].
Murthy K.H., Smith S.A., Ganesh V.K., Judge K.W., Mullins N., Barlow P.N., Ogata C.M., Kotwal G.J. Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans. Cell, 26, 104:301-11, 2001. Retraction in: Cell, Dec 13;175(7):1992.
Hicks R.R., Keeling K.L., Yang M.Y., Smith S.A., Simons A.M., Kotwal G.J. Vaccinia virus complement control protein enhances functional recovery following traumatic brain injury. Neurotrauma, Jun. 19(6):705-14, 2002.
Anderson J.B., Smith S.A., Kotwal G.J. Vaccinia virus complement control protein inhibits hyperacute xenorejection. Proc., Jun. 34(4):1083-5, 2002.
Smith S.A., Krishnasamy G., Murthy K.H., Cooper A., Bromek , Barlow P.N., Kotwal G.J. Vaccinia virus complement control protein is monomeric, and retains structural and functional integrity after exposure to adverse conditions. Biochim. Biophys. Acta., Jul. 29;1598(1-2):55-64, 2002.
Anderson J.B., Smith S.A., Wijk R.V., Chien S., Kotwal G.J. Vaccinia virus complement control protein ameliorates hyperacute xenorejection by inhibiting xenoantibody binding. Proc., Dec. 34(8):3277-81, 2002.
Smith S.A.*, Kahn D.*, Kotwal G.J. Dose-dependent inhibition of complement in baboons by vaccinia virus complement control protein: implications in xenotransplantation. Proc., Jun. 35(4):1606-8, 2003.
Anderson J.B., Smith S.A., Wijk R.V., Chien S., Kotwal G.J. Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activation. Immunol., 11(2):129-35, 2003.
Smith S.A., Sreenivasan R., Krishnasamy G., Judge K., Murthy K.H., Arjunwadkar S., Pugh D.R., Kotwal G.J. Mapping of regions within the vaccinia virus complement control protein involved in dose-dependent binding to key complement components and heparin using surface plasmon resonance. Biophys. Acta., Aug. 21;1650(1-2):30-39, 2003.
Jha P., Smith S.A., Justus D.E., Kotwal G.J. Prolonged retention of vaccinia virus complement control protein following I.P. injection: implications in blocking xenorejection. Proc., Dec. 35(8):3160-2, 2003.
Reynolds D.N., Smith S.A., Shields C.B., Zhang Y.P., Morassutti D.J., Kotwal G.J. Vaccinia virus complement control protein reduces neutrophil infiltration following spinal cord injury. NY Acad. Sci., Dec. 1010:534-9, 2003.
Ganesh V.K., Smith S.A., Kotwal G.J., Murthy K.H. Structure of vaccinia complement protein in complex with heparin and potential implications for complement regulation. Natl. Acad. Sci. USA, Jun. 15;101(24):8924-9, 2004. Retraction in: Proc. Natl. Acad. Sci. USA., Jul 17;115(29):E6965, 2018.
Billings B.B., Smith S.A., Zhang, Lahiri D., Kotwal G.J. Lack of N1L gene expression results in a significant decrease of vaccinia virus replication in mouse brain. Ann. NY Acad. Sci., Dec. 1030:297-302, 2004.
Reynolds D.N., Smith S.A., Kulkarni A.P., Zhang Y.P., Kellaway A., Morassutti D.J., Shields C.B., Kotwal G.J. Vaccinia Virus Complement Control Protein Reduces Inflammation and Improves Spinal Cord Integrity Following Spinal Cord Injury. Ann. NY Acad. Sci., Dec. 1035:165-178, 2004.
Schulz P., Allen M., Murray Q., Smith S.A., Carrico R., Goss L., Ramírez J. Infections due to Community-Acquired Methicillin Resistant Staphylococcus aureus: an Emergent Epidemic in Kentucky. Ky Med. Assoc., May 103(5):194-203, 2005.
Ganesh V.K., Muthuvel S.K., Smith S.A., Kotwal G.J., Murthy K.H. Structural Basis for Antagonism by Suramin of Heparin Binding to Vaccinia Complement Protein. Biochemistry. Aug. 44(32):10757-65, 2005. Retraction in: Biochemistry, Oct 16;57(41):6043.
Jha P., Smith S.A., Justus D.E., Kotwal G.J. Inhibition of complement system blocks the formation of osteoclast-like cells in collagen-induced arthritic in mice. NY Acad. Sci., Nov. 1056:55-68, 2005.
Smith C.S., Smith S.A., Grier T.J., Justus D.E. Aluminum sulfate significantly reduces the skin test response to common allergens in sensitized patients. Mol. Allergy, Feb. 14;4(1):1, 2006.
Krause J.C., Tsibane T., Tumpey T.M., Huffman C.J., Briney B., Smith S.A., Basler C.F., Crowe J.E. Jr. Epitope-specific human antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal J. Immunol., Oct. 1;187:3704-11, 2011.
Smith S.A., Zhou Y., Broadwater A.H., Olivarez N.P., Broadwater A.H., Desilva A.M., Crowe J.E. Jr. Persistence of circulating B memory cell clones with potential for dengue virus disease enhancement for decades following infection. Virol., Mar. 86(5):2665-75, 2012.
de Alwis R.S., Smith S.A., Olivarez N.P., Messer W.B., Hynh J.P., Wahala W.P.B., White L.J., Baric R.S., Crowe J.E., de Silva A.M. Molecular basis of dengue virus neutralization by human antibodies. Natl. Acad. Sci. USA., May 8;109(19):7439-44, 2012.
Smith S.A., de Alwis R.S., Kose N., Shresta S., Durbin A.P., Whitehead S.S., de Silva M., Crowe J.E. Jr. Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J. Infect. Dis., Jun. 207(12):1898-908, 2013.
Smith A., de Alwis R., Kose N., Harris E., Ibarra K., Kahle K.M., Pfaff J.M., Xiang X., Doranz B.J., de Silva A.M., Austin S.K., Sukupolvi-Petty S., Diamond M.S., Crowe J.E. Jr. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the BC loop of domain II of the envelope protein. MBio., Nov 19;4(6): e00873-13, 2013.
Fibriansah G., Tan J.L., Smith A., de Alwis A.R., Ng T., Kostyuchenko V.A., Ibarra K.D., Harris E., de Silva A.M., Crowe J.E., Lok S.M. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol. Med., Mar 1;6(3):358-71., 2014 [Cover of EMBO Mol. Med., Mar 1;6(3), 2014].
Messer W.B., de Alwis R., Yount B., Royal S., Huynh J., Smith S.A, Crowe J.E., Doranz B., White L.J., Sariol C.A., de Silva A.M., Baric R.S. The dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Natl. Acad. Sci. USA., Feb 4;111(5):1939-44., 2014. Retraction in: Proc. Natl. Acad. Sci. USA., May 19;112(20):E2738, 2015.
Smith S.A., de Alwis A.R., Kose , de Silva A.M., Crowe J.E. Jr. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J. Virol., Nov 1;88(21):12233-41., 2014.
de Alwis R.S., Williams K.L., Schmid M.A., Lai C.Y., Patel B., Smith S.A., Crowe J.E., Wang W.K., Harris E., de Silva A.M. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog., Oct 2;10(10): e1004386, 2014.
Fibriansah G., Tan L., Smith S.A., de Alwis R., Ng T., Kostyuchenk V.A., Jadi R.S., Petra Kukkaro P., de Silva A.M., Crowe J.E. Jr., Lok S.M. Extremely potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat. Commun., 6:6341, 2015.
Callaway J.B., Smith S.A., McKinnon K.P., de Silva A.M., Crowe J.E. Jr., Ting J.P.Y. Spleen tyrosine kinase (Syk) mediates IL-1β induction by primary human monocytes during antibody-enhanced dengue virus infection. Biol. Chem., Jul 10;290(28):17306-20, 2015.
Fibriansah G., Ibarra K.D., Ng S., Smith S.A., Tan J.L., Lim X., Ooi J.S., Kostyuchenk V.A., Wang J., de Silva A.M., Harris E., Crowe J.E. Jr., Lok S.M. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science, Jul 3;349(6243):88-91, 2015.
Smith S.A.*, Silva L.A.*, Fox J.M., Flyak A., Kose N., Sapparapu G., Khomadiak S., Ashbrook A.W., Kahle K.M, Fong R.H., Swayne S., Doranz B.J., McGee C.E., Heise M.T., Pal P., Brien J.D., Austin S.K., Diamond M.S., Dermody T.S., Crowe J.E. Jr. Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. Cell Host Microbe, Jul 8;18(1):86-95, 2015.
Callaway J.B., Smith S.A., Widman G., McKinnon K.P., Scholle F., Sempowski G.D., Dittmer D.P., Crowe J.E. Jr., de Silva A.M., Ting J.P. Source and purity of dengue-viral preparations impact requirement for enhancing antibody to induce elevated IL-1β secretion: a primary human monocyte model. PLoS One, Aug 24;10(8): e0136708, 2015.
Smith S.A., Nivarthi U.K., de Alwis , Kose N., Sapparapu G., Bombardi R., Kahle K.M., Pfaff J.M., Lieberman S, Doranz B.J., de Silva A.M., Crowe J.E. Jr. Dengue virus prM-specific human monoclonal antibodies with virus replication enhancing properties recognize a single immunodominant antigenic site. J. Virol., Oct 28;90(2):780-9, 2015.
Messer W.B., Yount B., Royal S., de Alwis A.R., Widman D.G., Smith S.A, Crowe J.E., Pfaff J.M., Kahle M., Doranz B.J., Ibarra K., Harris E., Baric R.S., de Silva A.M. Functional Transplant of a Dengue Virus Type 3 Human Antibody Epitope into Dengue Virus Type 1. J. Virol., Apr 29;90(10):5090-7, 2016.
Wurth M.A., Hadadianpour A., Horvath D.J., Daniel J., Bogdan O., Goleniewska K., Pomés A., Hamilton R.G., Peebles R.S. Jr., Smith S.A. Human IgE mAbs define variability in commercial Aspergillus extract allergen composition. JCI Insight, 3(20):e123387, 2018.
Wirawan M., Fibriansah G., Marzinek J.K., Lim X., Ng S., Sim A.L., Zhang Q., Kostyuchenko V.A., Shi J., Smith S.A., Verma C.S., Anand G., Crowe J.E. Jr., Bond P., Lok S.M. Mechanism of enhanced immature dengue virus attachment to endosomal membrane induced by prM antibody. Structure, Feb 5;27(2):253-267, 2019.
Duan S, Koziol-White CJ, Jester WF Jr, Smith S.A., Nycholat CM, Macauley MS, Panettieri RA Jr, Paulson JC. CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen. J Clin Invest., Mar 1;129(3):1387-1401, 2019.
Newman J.H., Shaver A., Sheehan J.H., Mallal S., Stone J.H., Pillai S., Bastarache L., Riebau D., Allard-Chamard H., Stone W.M., Perugino C., Pilkinton M., Smith S.A., McDonnell W.J., Capra T., Meiler J., Cogan J., Xing K., Mahajan V.S., Mattoo H., Hamid R., Phillips J.A. III. IgG4-Related Disease: Association with a Rare Gene Variant Expressed in Cytotoxic T Cells. Mol Genet Genomic Med., Apr 16:e686, 2019.
Mueller G.A., Glesner J., Daniel J.L., Zhang J., Hyduke N., Richardson C., DeRose E.F., Chapman M., Peebles R.S., Smith S.A.*, Pomés A*. Mapping human monoclonal IgE epitopes on the major dust mite allergen Der p 2. J Immunol., Oct 15;205(8):1999-2007, 2020.
Young-Glazer J., Cisneros A. 3rd, Wilfong E.M., Smith S.A., Crofford L.J., Bonami R.H. Jo-1 autoantigen-specific B cells are skewed towards distinct functional B cell subsets in anti-synthetase syndrome patients. Arthritis Res Ther., Jan 19;23(1):33, 2021.
Duan S., Arlian B.M., Nycholat C.M., Wei Y.‚ Tateno H., Smith S.A., Macauley M.S., Zhu Z., Bochner B.S., Paulson J.C. Nanoparticles displaying allergen and Siglec-8 ligands suppress IgE-FceRI mediated anaphylaxis and desensitize mast cells to subsequent antigen challenge. J Immunol., May 15;206(10):2290-2300, 2021.
Joosse B.A., Jackson J.H., Cisneros A., Santhin A.B., Smith S.A., Moore D.J., Crofford L.J., Wilfong E.M., Bonami R.H. High-Throughput Detection of Autoantigen-Specific B Cells among Distinct Functional Subsets in Autoimmune Donors. Front Immunol., May 24;12:685718, 2021.
Islam M., Arlian B.M., Pfrengle F., Duan S., Smith S.A., Paulson J.C. Suppressing Immune Responses using Siglec Ligand Decorated Anti-Receptor Antibodies. J Am Chem Soc., Jun 1;144(21):9302-9311, 2022.
Khatri K., Richardson M., Glesner J., Kapingidza A.B., Mueller G.A., Zhang J., Dolamore C., Vailes L.D., Wünschmann S., Peebles R.S. Jr., Chapman M.D., Smith S.A., Chruszcz M., Pomés A. Human IgE monoclonal antibody recognition of mite allergen Der p 2 defines structural basis of an epitope for IgE cross-linking and anaphylaxis in vivo. PNAS Nexus, Jun 2;1(3):pgac054, 2022.
Hadadianpour A., Daniel J., Zhang J., Spiller B.W., Makaraviciute A., DeWitt Å.M., Walden H.S., Hamilton R.G., Peebles R.S. Jr, Nutman T.B., Smith S.A. Human IgE mAbs identify major antigens of parasitic worm infection. J Allergy Clin Immunol. Jun 24:S0091-6749(22)00843-0, 2022.
Suber J., Zhang Y., Ye P., Guo R., Burks W.A., Kulis M.D., Smith S.A., Iweala O.I. Novel peanut-specific human IgE monoclonal antibodies enable screens for inhibitors of the effector phase in food allergy. Front Immunol., 13:974374, 2022.
Alakhras S., Shin J., Smith S.A., Sinn A.L., Zhang W., Pollok K.E., Bilgicer B., Kaplan M.H. Peanut allergen-specific inhibition of anaphylaxis in a humanized mouse model. Sci Transl Med. Feb 8;15(682):eadd6373, 2023.
Pena-Castellanos G., Smith B.R.E., Pomés A., Smith S.A., Stigler M.A., Widauer H.L., Versteeg S.A., van Ree R., Chapman M.D., Aglas L. Biological activity of human IgE monoclonal antibodies targeting Der p 2, Fel d 1, Ara h 2 in basophil mediator release assays. Front Immunol. May 9;14:1155613, 2023.
Stone C.A. Jr, Hemler J.A., Filep S., Braden K., Pomés A., Chapman M.D., Smith S.A. Quantification of peanut allergens across recalled and nonrecalled lots of diagnostic peanut extracts. J Allergy Clin Immunol Pract. Jul 17:S2213-2198(23)00786-9, 2023.
Smith B.R.E., Reid Black K., Bermingham M., Agah S., Glesner J., Versteeg S.A., van Ree R., Pena-Amelunxen G., Aglas L., Smith S.A., Pomés A., Chapman M.D. Unique allergen-specific human IgE monoclonal antibodies derived from patients with allergic disease. Front Allergy. Oct 12;4:1270326, 2023.
Katru S.C., Balakrishnan A.S., Munirathinam G., Hadadianpour A., Smith S.A., Kalyanasundaram R. Identification and characterization of a novel nematode pan allergen (NPA) from Wuchereria bancrofti and their potential role in human filarial tropical pulmonary eosinophilia (TPE). PLoS Negl Trop Dis. Feb 14;18(2):e0011972, 2024.
Ball A., Khatri K., Glesner J., Vailes L.D., Wünschmann S., Gabel S.A., Mueller G.A., Zhang J., Peebles R.S. Jr., Chapman M.D., Smith S.A., Chruszcz M., Pomés A. Structural Analysis of Human IgE Monoclonal Antibody Epitopes on Dust Mite Allergen Der p 2. J Allergy Clin Immunol. Apr 30:S0091-6749(24)00421-4, 2024.
Smith S.A., Khan Y.W., Shrem R.A., Hemler J.A., Doyle J.E., Daniel J., Zhang J., Pena-Amelunxen G., Aglas L., Hamilton R.G., Getts R., Sampson H.A., Wong J.J.W., Croote D., Peebles R.S. Jr., Spiller W. Antigenic determinants underlying IgE-mediated anaphylaxis to peanut. J Allergy Clin Immunol., in press, 2024.
Smith S.A., Shrem R.A., Lança B.C, Zhang J., Wong J.J.W., Croote D., Peebles R.S. Jr., Spiller B.W. Structural determinants of peanut induced anaphylaxis. J Allergy Clin Immunol., in press, 2024.

Peer-Reviewed Review Articles and Book Chapters:

Smith S.A., and Kotwal G.J. Virokines: novel immunomodulatory agents. Opin. Biol. Ther., 1(3):343-357, 2001.
Smith S.A., and Kotwal G.J. Vaccinia virus. In: Encyclopedia of Molecular Medicine. John Wiley & Sons Inc., Vol. 5, pp. 3324-3330, 2001.
Smith S.A., and Kotwal G.J. Immune response to poxvirus infections in various animals. Rev. Microbiol., 28(3):149-186, 2002.
Ghebremariam Y.T., Smith S.A., Anderson J.B., Kahn D., Kotwal G.J. Human Xenotransplantation: An Immunological & Ethical Challenge. In: New Research on Immunology. Nova Science Publishers, pp. 127-145, 2005; and Contemporary Ethical Issues, Nova Science Publishers, pp. 63-86, 2005.
Ghebremariam Y.T., Smith S.A., Anderson J.B., Kahn D., Kotwal G.J. Intervention strategies and agents mediating the prevention of xenorejection. NY Acad. Sci., Nov. 1056:123-43, 2005.
Smith S.A. and Crowe J.E. Jr. Use of human hybridoma technology to isolate human monoclonal antibodies. In: Antibodies for Infectious Diseases, ASM Press, 1^st edition, Crowe JE Jr, Boraschi D, Rappuoli R, eds., 2015; and Microbiol Spectrum 3(1):AID-0027-2014, 2015.
Smith S.A., Chruszcz M., Chapman M.D., Pomés A. Human Monoclonal IgE Antibodies-a Major Milestone in Allergy. Curr Allergy Asthma Rep. Jan;23(1):53-65, 2023.
Stone C.A. Jr., Spiller B.W., Smith S.A. Engineering therapeutic monoclonal antibodies. J Allergy Clin Immunol. 2023 Nov 21:S0091-6749(23)01476-8.
Pomés A., Smith S.A., Chruszcz M., Mueller G.A., Brackett N.F., Chapman M.D. Precision engineering for localization, validation, and modification of allergenic epitopes. J Allergy Clin Immunol. 2024 Jan 3:S0091-6749(24)00001-0.